Hot Products

Products Categories

Inositol Nicotinate / Inositol Hexanicotinate/ Inositol Hexaniacinate / Myo-Inositol Nicotinateiamine disulfide

Bisbentiamine / Bithiamin / Thiamine disulfide / Benzoylthiamine disulfide

Calcium Pyruvate / Pyruvic Acid Calcium

Sodium Pyruvate / Sodium Pyroracemate/ Sodium 2-oxopropanoate

Pyruvic Acid/ 2-Ketopropionic Acid/ ACETYLFORMIC ACID

Vitamin E Calcium Succinat / Vitamin E Derivatives/ Vitamin E Salt

Sulbutiamine/ Bisibutiamine/ Vitamin B1 derivative/ Synthetic derivative of thiamine

R-(+)-Lipoic Acid / R-ALA / (R)-Alpha-Lipoic Acid

O-Phospho-L-threonine L-Phosphothreonine/ Threoninium Dihydrogen Phosphate/ O-Phosphothreonine

O-Phospho-DL-serine / Serophen / DL-O-phosphoserine / DL-O-phosphoserinate

0102030405

Benfotiamine: High Bioavailability Lipid-Soluble Vitamin B1 from China Suppliers & Factory

Benfotiamine is a lipid-soluble derivative of vitamin B1, recognized for its superior bioavailability and bioactivity—approximately 3.6 times more effective than standard water-soluble vitamin BThis potent form of vitamin B1 addresses the low bioavailability associated with traditional variants. As one of the leading suppliers and factories in China, we are committed to providing high-quality benfotiamine that enhances your health and well-being. Choose us for premium products that leverage the benefits of this remarkable nutrient

CAS: 22457-89-2

Product Detail

Molecular Formula

C₁₉H₂₃N₄O₆PS

Benfotiamine Structural Formula C19H23N4O6PS

Description

As a synthetic derivative of vitamin B1 (thiamine), benfotiamine significantly surpasses ordinary vitamin B1 in bioavailability, targeting and clinical efficacy through structural optimization and pharmacokinetic improvement. The specific advantages are as follows:

Structural Innovation: Lipid-Soluble Modification Breaks Through Absorption Limitations

Ordinary vitamin B1 (thiamine) is a water-soluble molecule that relies on intestinal sodium-dependent carriers (ThTr1/2) for active transport. It has a low absorption rate (<5%) and is easily saturated. High doses are easily excreted.

Benfotiamine is converted into a lipid-soluble prodrug by introducing benzoyl and phosphate groups (structural formula C₁₉H₂₃N₄O₆PS), which can bypass carrier restrictions and directly penetrate intestinal mucosal cells through passive diffusion.

>80%

Absorption Efficiency
(Benfotiamine)

<5%

Absorption Rate
(Ordinary B1)

3–5×

Higher Bioavailability
(J Clin Pharmacol, 2008)

Pharmacokinetic Advantages: Long-Term Effect and Tissue Targeting

Ordinary B1 has a short half-life in the blood (about 3.5 hours) and is easily cleared quickly by the kidneys. Benfotiamine is hydrolyzed into active thiamine by phosphatase in the body and further converted into thiamine pyrophosphate (TPP).

Extended half-life: Its lipid solubility promotes accumulation in the phospholipid layer of the cell membrane, prolonging the duration of action to >6 hours (vs ~3.5 hours for ordinary B1).

Superior CNS penetration: Its ability to penetrate the blood-brain barrier and nerve sheath is 8–10× greater than ordinary B1, effectively acting on both central and peripheral nervous systems (Neurochem Res, 2016).

Metabolic Regulation: Multi-Target Inhibition of Glucotoxic Damage

In a hyperglycemic environment, ordinary B1 is difficult to effectively inhibit abnormal glucose metabolism pathways due to poor tissue permeability. Benfotiamine shows unique advantages through the following mechanisms:

Blocking AGEs generation: Inhibiting hexosamine and polyol pathways, reducing the accumulation of advanced glycation end products (AGEs), and alleviating axonal damage in diabetic neuropathy (Diabetes, 2010).

Anti-inflammatory & antioxidant: Downregulating the activity of NF-κB and TXNIP/NLRP3 inflammasomes, reducing inflammatory factors such as IL-6 and TNF-α, while enhancing glutathione reductase activity and alleviating oxidative stress.

Mitochondrial protection: Restoring the function of pyruvate dehydrogenase complex (PDH), improving the efficiency of tricarboxylic acid cycle, and reducing lactic acid accumulation.

Clinical Efficacy: High-Dose Tolerance and Deep Repair

Ordinary B1 requires extremely high doses (≥300 mg/day) to treat diabetic neuropathy, but its efficacy is limited due to its absorption rate. Benfotiamine can stably increase tissue TPP concentration within the dose range of 150–600 mg/day.

+2.1 m/s

Improved nerve
conduction velocity
vs placebo

−40%

Reduction in
pain scores (VAS)

✓ Safe

No liver/kidney
toxicity reported
(Diabetes Care, 2005)

Stability and Compatibility of Preparations

Benfotiamine is significantly more stable than ordinary B1 in an acidic environment (pH 2.0–4.0), and is compatible with a variety of multivitamins or drug preparations.

Acid-environment degradation rate: Benfotiamine <5% vs Ordinary B1 >30% (pH 2.0–4.0)

Advanced delivery systems: Its lipid-soluble properties support the development of nanoemulsions and liposomes, further improving the efficiency of targeted delivery.

Frequently Asked Questions

Q1 What is benfotiamine and how does it differ from regular vitamin B1?

Benfotiamine is a synthetic, lipid-soluble derivative of vitamin B1 (thiamine). Unlike ordinary water-soluble thiamine, which relies on intestinal carriers and has low absorption (<5%), benfotiamine bypasses these limitations through passive diffusion, achieving absorption efficiency of over 80% and bioavailability 3–5 times higher than standard B1.

Q2 Why is benfotiamine more effective for nerve health than regular thiamine?

Benfotiamine's lipid-soluble nature allows it to penetrate the blood-brain barrier and nerve sheath 8–10 times more effectively than ordinary B1. It accumulates in cell membrane phospholipid layers, extending its half-life beyond 6 hours and enabling sustained action on both central and peripheral nervous systems.

Q3 How does benfotiamine help people with diabetic neuropathy?

Benfotiamine targets multiple pathways involved in glucose-related damage: it blocks the formation of advanced glycation end products (AGEs), suppresses inflammatory pathways (NF-κB, TXNIP/NLRP3), reduces oxidative stress, and protects mitochondrial function. Clinical trials have demonstrated improved nerve conduction velocity (+2.1 m/s vs placebo) and a 40% reduction in pain scores (VAS).

Q4 What is the recommended dosage of benfotiamine, and is it safe at higher doses?

Benfotiamine is typically studied and used in the range of 150–600 mg/day. Within this range, it has been shown to stably increase tissue thiamine pyrophosphate (TPP) levels with no reported liver or kidney toxicity, making it well-tolerated even at higher therapeutic doses compared to ordinary B1.

Q5 Is benfotiamine stable in acidic environments such as the stomach?

Yes. Benfotiamine demonstrates significantly greater stability than ordinary B1 in acidic conditions (pH 2.0–4.0), with a degradation rate of less than 5% compared to over 30% for regular thiamine. This stability makes it suitable for a wide range of formulations including tablets, capsules, and advanced delivery systems like nanoemulsions and liposomes.

Q6 Can benfotiamine be combined with other vitamins or supplements?

Benfotiamine is compatible with a variety of multivitamin formulations and pharmaceutical preparations. Its lipid-soluble properties and stability profile make it an excellent candidate for combination products. However, as with all supplements, it is advisable to consult a healthcare professional before combining with prescription medications.